Spyre Therapeutics Inc. stocks have been trading up by 28.59 percent following highly positive clinical trial advancement news.
Click Here for a Millionaire's POV on Trading SYRE
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- Wall Street support strengthened after a major bank lifted its price target on the stock and reiterated a Buy rating tied to upcoming TL1A data.
- SYRE finished rheumatoid arthritis enrollment in its SKYWAY trial ahead of plan, pulling key topline data into Q3 2026 and tightening the catalyst calendar.
- The SKYLINE ulcerative colitis trial is enrolling faster than expected, with Part A induction data for SPY001 now due in Q2 2026 and a topline release set for 2026/04/13.
- Additional SKYWAY arms in psoriatic arthritis and axial spondyloarthritis remain on schedule for Q4 2026, and shares popped more than 6% on the development update.
- Option grants to new employees at $48.90 suggest Spyre Therapeutics is staffing up to support its TL1A pipeline, with modest long-term dilution.
Live Update At 10:02:24 EDT: On Monday, April 13, 2026 Spyre Therapeutics Inc. stock [NASDAQ: SYRE] is trending up by 28.59%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
Spyre Therapeutics, trading as SYRE, has been moving like a classic high‑expectation biotech. Over the past few weeks, the stock ran from the low $40s to the mid‑$60s, with the latest close near $66 after touching $75 intraday. That is a huge percentage move in a short window, and traders need to respect both the momentum and the risk.
Financially, SYRE is still a development‑stage name. The latest quarterly report shows no product revenue and a net loss of about $62.5M, or roughly $0.74 per share. The company is burning cash — operating cash flow was around -$44.6M — but the balance sheet is strong, with about $756.5M in cash and short‑term investments and essentially no debt. A current ratio above 13 means SYRE has plenty of liquidity to fund trials.
More Breaking News
- LCID Stock Slides As Recalls And Targets Hit EV Sentiment
- EVTL Stock Plunges As Vertical Aerospace Faces Going‑Concern And Legal Heat
- YETI Stock Slips As UBS Trims Price Target
- BZAI Jumps As Blaize-Nokia AI Partnership Expands In Asia
Returns on assets and equity are deeply negative, as you’d expect for a clinical‑stage biotech spending heavily on research. Traders watching SYRE should see this as a “pipeline versus cash” story: the runway looks solid, so the stock is going to trade primarily on trial headlines, analyst calls, and sentiment swings around the TL1A platform.
Why Traders Are Watching SYRE Now
SYRE is squarely on momentum traders’ screens after a powerful combination of bullish news. The headline catalyst is Stifel lifting its price target on Spyre Therapeutics from $70 to $92 while reiterating a Buy rating. For an early‑stage biotech, that kind of Street call matters. It signals that at least one major shop believes the TL1A strategy in inflammatory bowel disease and related conditions deserves a higher valuation as data approaches.
Under the hood, the clinical news flow explains why trading has heated up. Spyre Therapeutics completed enrollment ahead of expectations in the rheumatoid arthritis arm of its SKYWAY Phase 2 basket trial. That may sound like a dry line from a press release, but for traders it’s simple: faster enrollment means pulled‑forward data, and pulled‑forward data means the stock’s catalyst clock just sped up. Week‑12 topline results for this rheumatoid arthritis sub‑study are now slated for Q3 2026.
At the same time, SYRE is running a broad program. Enrollment in the psoriatic arthritis and axial spondyloarthritis arms of SKYWAY is on schedule, with topline results targeted for Q4 2026. The SKYLINE ulcerative colitis platform trial is enrolling ahead of plan as well, with Part A induction data expected in Q2 2026. When the company updated traders on this whole package, SYRE shares jumped more than 6%, a clear sign the market is rewarding execution and the stacked catalyst path.
On top of that, Spyre Therapeutics has locked in a near‑term date: it plans to release Part A induction topline results from SKYLINE’s SPY001 ulcerative colitis study on 2026/04/13, followed by a conference call. That is the kind of fixed event date momentum traders love to circle on their calendars.
Conclusion
Put it all together and SYRE is shaping up as a classic catalyst‑driven biotech for active trading. Spyre Therapeutics has cash to run multiple TL1A programs, and Wall Street is leaning constructive, highlighted by Stifel’s price‑target hike to $92. The stock has already shown what happens when news hits — a more than 6% spike on the SKYWAY update — and the chart now reflects a strong uptrend from the low $40s to the mid‑$60s, with wild intraday ranges like the recent $67–$75 swing.
Traders still need to remember what powers that volatility. SYRE is losing money by design as it spends heavily on research, and key ratios like negative return on assets and equity confirm this is all about future potential. The upcoming SKYLINE ulcerative colitis readout on 2026/04/13, plus rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis data in 2026, turns Spyre Therapeutics into a steady drumbeat of possible gap‑up or gap‑down days.
Those Form 4 insider ownership changes and the 70,200 new stock options at $48.90 are background noise compared with that data calendar. For traders who study the news, the filings, and the chart, SYRE offers both opportunity and risk. Active day‑by‑day execution matters here; as Tim Bohen, lead trainer with StocksToTrade says, “The best way to learn is by tracking trades, wins, losses, and lessons learned. Every trade has something to teach.”. As Tim Sykes loves to say, “Patterns repeat, but they don’t always complete — that’s why you plan the trade and cut losses quickly.” That mindset applies perfectly to Spyre Therapeutics right now.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.